Bayer To Market Alza Viadur In U.S.; Weighs International Agreement
Executive Summary
Bayer is considering an international marketing arrangement for Alza's Viadur following an agreement to market the long-acting leuprolide acetate implant for prostate cancer in the U.S.
You may also be interested in...
Alza Considering Viadur Marketing Partner For Late 2000 Launch
Alza is considering whether to find a marketing partner for Viadur in anticipation of a late 2000/early 2001 launch for the long-acting implant for palliative treatment of advanced prostate cancer.
Abbott And Alza Will Discuss Ditropan XL Copromotion In Merger Post-Mortem
Abbott and Alza are discussing whether the five-year copromotion agreement for Alza's Ditropan XL (oxybutynin) will survive the Dec. 16 collapse of the pending merger.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011